Caveolin-1 Gene Therapy Shows Promise Against TDP-43 Neurodegeneration
New research reveals that a systemic gene therapy targeting caveolin-1 can reduce TDP-43 proteinopathy in a mouse model, offering a novel approach for neurodegenerative diseases like ALS and LATE.